Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Growth 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.
LPI (LP Information)' newest research report, the “Glucagon-like peptide 1 (GLP-1)-based Therapies Industry Forecast” looks at past sales and reviews total world Glucagon-like peptide 1 (GLP-1)-based Therapies sales in 2022, providing a comprehensive analysis by region and market sector of projected Glucagon-like peptide 1 (GLP-1)-based Therapies sales for 2023 through 2029. With Glucagon-like peptide 1 (GLP-1)-based Therapies sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Glucagon-like peptide 1 (GLP-1)-based Therapies industry.
This Insight Report provides a comprehensive analysis of the global Glucagon-like peptide 1 (GLP-1)-based Therapies landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Glucagon-like peptide 1 (GLP-1)-based Therapies portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Glucagon-like peptide 1 (GLP-1)-based Therapies market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Glucagon-like peptide 1 (GLP-1)-based Therapies and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Glucagon-like peptide 1 (GLP-1)-based Therapies.
The global Glucagon-like peptide 1 (GLP-1)-based Therapies market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Glucagon-like peptide 1 (GLP-1)-based Therapies is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Glucagon-like peptide 1 (GLP-1)-based Therapies is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Glucagon-like peptide 1 (GLP-1)-based Therapies is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Glucagon-like peptide 1 (GLP-1)-based Therapies players cover Novo Nordisk, AstraZeneca, Eli Lily, GSK, Sanofi and Bristol-Myers Squibb, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Glucagon-like peptide 1 (GLP-1)-based Therapies market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
What is the 10-year outlook for the global Glucagon-like peptide 1 (GLP-1)-based Therapies market?
What factors are driving Glucagon-like peptide 1 (GLP-1)-based Therapies market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Glucagon-like peptide 1 (GLP-1)-based Therapies market opportunities vary by end market size?
How does Glucagon-like peptide 1 (GLP-1)-based Therapies break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.
LPI (LP Information)' newest research report, the “Glucagon-like peptide 1 (GLP-1)-based Therapies Industry Forecast” looks at past sales and reviews total world Glucagon-like peptide 1 (GLP-1)-based Therapies sales in 2022, providing a comprehensive analysis by region and market sector of projected Glucagon-like peptide 1 (GLP-1)-based Therapies sales for 2023 through 2029. With Glucagon-like peptide 1 (GLP-1)-based Therapies sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Glucagon-like peptide 1 (GLP-1)-based Therapies industry.
This Insight Report provides a comprehensive analysis of the global Glucagon-like peptide 1 (GLP-1)-based Therapies landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Glucagon-like peptide 1 (GLP-1)-based Therapies portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Glucagon-like peptide 1 (GLP-1)-based Therapies market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Glucagon-like peptide 1 (GLP-1)-based Therapies and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Glucagon-like peptide 1 (GLP-1)-based Therapies.
The global Glucagon-like peptide 1 (GLP-1)-based Therapies market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Glucagon-like peptide 1 (GLP-1)-based Therapies is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Glucagon-like peptide 1 (GLP-1)-based Therapies is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Glucagon-like peptide 1 (GLP-1)-based Therapies is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Glucagon-like peptide 1 (GLP-1)-based Therapies players cover Novo Nordisk, AstraZeneca, Eli Lily, GSK, Sanofi and Bristol-Myers Squibb, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Glucagon-like peptide 1 (GLP-1)-based Therapies market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
- Exenatied
- Liraglutide
- Lixisenatide
- Albiglutide
- Dulaglutide
- Hospital
- Pharmacy
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Novo Nordisk
- AstraZeneca
- Eli Lily
- GSK
- Sanofi
- Bristol-Myers Squibb
What is the 10-year outlook for the global Glucagon-like peptide 1 (GLP-1)-based Therapies market?
What factors are driving Glucagon-like peptide 1 (GLP-1)-based Therapies market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Glucagon-like peptide 1 (GLP-1)-based Therapies market opportunities vary by end market size?
How does Glucagon-like peptide 1 (GLP-1)-based Therapies break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Glucagon-like peptide 1 (GLP-1)-based Therapies by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Glucagon-like peptide 1 (GLP-1)-based Therapies by Country/Region, 2018, 2022 & 2029
2.2 Glucagon-like peptide 1 (GLP-1)-based Therapies Segment by Type
2.2.1 Exenatied
2.2.2 Liraglutide
2.2.3 Lixisenatide
2.2.4 Albiglutide
2.2.5 Dulaglutide
2.3 Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type
2.3.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type (2018-2023)
2.3.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue and Market Share by Type (2018-2023)
2.3.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sale Price by Type (2018-2023)
2.4 Glucagon-like peptide 1 (GLP-1)-based Therapies Segment by Application
2.4.1 Hospital
2.4.2 Pharmacy
2.5 Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application
2.5.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sale Market Share by Application (2018-2023)
2.5.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue and Market Share by Application (2018-2023)
2.5.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sale Price by Application (2018-2023)
3 GLOBAL GLUCAGON-LIKE PEPTIDE 1 (GLP-1)-BASED THERAPIES BY COMPANY
3.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Breakdown Data by Company
3.1.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Annual Sales by Company (2018-2023)
3.1.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Company (2018-2023)
3.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Annual Revenue by Company (2018-2023)
3.2.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Company (2018-2023)
3.2.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Company (2018-2023)
3.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sale Price by Company
3.4 Key Manufacturers Glucagon-like peptide 1 (GLP-1)-based Therapies Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Glucagon-like peptide 1 (GLP-1)-based Therapies Product Location Distribution
3.4.2 Players Glucagon-like peptide 1 (GLP-1)-based Therapies Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR GLUCAGON-LIKE PEPTIDE 1 (GLP-1)-BASED THERAPIES BY GEOGRAPHIC REGION
4.1 World Historic Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Geographic Region (2018-2023)
4.1.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Country/Region (2018-2023)
4.2.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Annual Sales by Country/Region (2018-2023)
4.2.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Annual Revenue by Country/Region (2018-2023)
4.3 Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Growth
4.4 APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Growth
4.5 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Growth
4.6 Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Growth
5 AMERICAS
5.1 Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country
5.1.1 Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2018-2023)
5.1.2 Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2018-2023)
5.2 Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type
5.3 Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region
6.1.1 APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region (2018-2023)
6.1.2 APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Region (2018-2023)
6.2 APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type
6.3 APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies by Country
7.1.1 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2018-2023)
7.1.2 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2018-2023)
7.2 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type
7.3 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies by Country
8.1.1 Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2018-2023)
8.1.2 Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2018-2023)
8.2 Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type
8.3 Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Glucagon-like peptide 1 (GLP-1)-based Therapies
10.3 Manufacturing Process Analysis of Glucagon-like peptide 1 (GLP-1)-based Therapies
10.4 Industry Chain Structure of Glucagon-like peptide 1 (GLP-1)-based Therapies
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Glucagon-like peptide 1 (GLP-1)-based Therapies Distributors
11.3 Glucagon-like peptide 1 (GLP-1)-based Therapies Customer
12 WORLD FORECAST REVIEW FOR GLUCAGON-LIKE PEPTIDE 1 (GLP-1)-BASED THERAPIES BY GEOGRAPHIC REGION
12.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Region
12.1.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Forecast by Region (2024-2029)
12.1.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Forecast by Type
12.7 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Novo Nordisk
13.1.1 Novo Nordisk Company Information
13.1.2 Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolios and Specifications
13.1.3 Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Novo Nordisk Main Business Overview
13.1.5 Novo Nordisk Latest Developments
13.2 AstraZeneca
13.2.1 AstraZeneca Company Information
13.2.2 AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolios and Specifications
13.2.3 AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 AstraZeneca Main Business Overview
13.2.5 AstraZeneca Latest Developments
13.3 Eli Lily
13.3.1 Eli Lily Company Information
13.3.2 Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolios and Specifications
13.3.3 Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Eli Lily Main Business Overview
13.3.5 Eli Lily Latest Developments
13.4 GSK
13.4.1 GSK Company Information
13.4.2 GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolios and Specifications
13.4.3 GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 GSK Main Business Overview
13.4.5 GSK Latest Developments
13.5 Sanofi
13.5.1 Sanofi Company Information
13.5.2 Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolios and Specifications
13.5.3 Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Sanofi Main Business Overview
13.5.5 Sanofi Latest Developments
13.6 Bristol-Myers Squibb
13.6.1 Bristol-Myers Squibb Company Information
13.6.2 Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolios and Specifications
13.6.3 Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Bristol-Myers Squibb Main Business Overview
13.6.5 Bristol-Myers Squibb Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Glucagon-like peptide 1 (GLP-1)-based Therapies by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Glucagon-like peptide 1 (GLP-1)-based Therapies by Country/Region, 2018, 2022 & 2029
2.2 Glucagon-like peptide 1 (GLP-1)-based Therapies Segment by Type
2.2.1 Exenatied
2.2.2 Liraglutide
2.2.3 Lixisenatide
2.2.4 Albiglutide
2.2.5 Dulaglutide
2.3 Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type
2.3.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type (2018-2023)
2.3.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue and Market Share by Type (2018-2023)
2.3.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sale Price by Type (2018-2023)
2.4 Glucagon-like peptide 1 (GLP-1)-based Therapies Segment by Application
2.4.1 Hospital
2.4.2 Pharmacy
2.5 Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application
2.5.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sale Market Share by Application (2018-2023)
2.5.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue and Market Share by Application (2018-2023)
2.5.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sale Price by Application (2018-2023)
3 GLOBAL GLUCAGON-LIKE PEPTIDE 1 (GLP-1)-BASED THERAPIES BY COMPANY
3.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Breakdown Data by Company
3.1.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Annual Sales by Company (2018-2023)
3.1.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Company (2018-2023)
3.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Annual Revenue by Company (2018-2023)
3.2.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Company (2018-2023)
3.2.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Company (2018-2023)
3.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sale Price by Company
3.4 Key Manufacturers Glucagon-like peptide 1 (GLP-1)-based Therapies Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Glucagon-like peptide 1 (GLP-1)-based Therapies Product Location Distribution
3.4.2 Players Glucagon-like peptide 1 (GLP-1)-based Therapies Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR GLUCAGON-LIKE PEPTIDE 1 (GLP-1)-BASED THERAPIES BY GEOGRAPHIC REGION
4.1 World Historic Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Geographic Region (2018-2023)
4.1.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Country/Region (2018-2023)
4.2.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Annual Sales by Country/Region (2018-2023)
4.2.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Annual Revenue by Country/Region (2018-2023)
4.3 Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Growth
4.4 APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Growth
4.5 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Growth
4.6 Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Growth
5 AMERICAS
5.1 Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country
5.1.1 Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2018-2023)
5.1.2 Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2018-2023)
5.2 Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type
5.3 Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region
6.1.1 APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region (2018-2023)
6.1.2 APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Region (2018-2023)
6.2 APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type
6.3 APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies by Country
7.1.1 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2018-2023)
7.1.2 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2018-2023)
7.2 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type
7.3 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies by Country
8.1.1 Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2018-2023)
8.1.2 Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2018-2023)
8.2 Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type
8.3 Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Glucagon-like peptide 1 (GLP-1)-based Therapies
10.3 Manufacturing Process Analysis of Glucagon-like peptide 1 (GLP-1)-based Therapies
10.4 Industry Chain Structure of Glucagon-like peptide 1 (GLP-1)-based Therapies
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Glucagon-like peptide 1 (GLP-1)-based Therapies Distributors
11.3 Glucagon-like peptide 1 (GLP-1)-based Therapies Customer
12 WORLD FORECAST REVIEW FOR GLUCAGON-LIKE PEPTIDE 1 (GLP-1)-BASED THERAPIES BY GEOGRAPHIC REGION
12.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Region
12.1.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Forecast by Region (2024-2029)
12.1.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Forecast by Type
12.7 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Novo Nordisk
13.1.1 Novo Nordisk Company Information
13.1.2 Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolios and Specifications
13.1.3 Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Novo Nordisk Main Business Overview
13.1.5 Novo Nordisk Latest Developments
13.2 AstraZeneca
13.2.1 AstraZeneca Company Information
13.2.2 AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolios and Specifications
13.2.3 AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 AstraZeneca Main Business Overview
13.2.5 AstraZeneca Latest Developments
13.3 Eli Lily
13.3.1 Eli Lily Company Information
13.3.2 Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolios and Specifications
13.3.3 Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Eli Lily Main Business Overview
13.3.5 Eli Lily Latest Developments
13.4 GSK
13.4.1 GSK Company Information
13.4.2 GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolios and Specifications
13.4.3 GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 GSK Main Business Overview
13.4.5 GSK Latest Developments
13.5 Sanofi
13.5.1 Sanofi Company Information
13.5.2 Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolios and Specifications
13.5.3 Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Sanofi Main Business Overview
13.5.5 Sanofi Latest Developments
13.6 Bristol-Myers Squibb
13.6.1 Bristol-Myers Squibb Company Information
13.6.2 Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolios and Specifications
13.6.3 Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Bristol-Myers Squibb Main Business Overview
13.6.5 Bristol-Myers Squibb Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Glucagon-like peptide 1 (GLP-1)-based Therapies Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Glucagon-like peptide 1 (GLP-1)-based Therapies Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Exenatied
Table 4. Major Players of Liraglutide
Table 5. Major Players of Lixisenatide
Table 6. Major Players of Albiglutide
Table 7. Major Players of Dulaglutide
Table 8. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type (2018-2023) & (Units)
Table 9. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type (2018-2023)
Table 10. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Type (2018-2023) & ($ million)
Table 11. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Type (2018-2023)
Table 12. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sale Price by Type (2018-2023) & (US$/Unit)
Table 13. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2018-2023) & (Units)
Table 14. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application (2018-2023)
Table 15. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Application (2018-2023)
Table 16. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Application (2018-2023)
Table 17. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sale Price by Application (2018-2023) & (US$/Unit)
Table 18. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Company (2018-2023) & (Units)
Table 19. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Company (2018-2023)
Table 20. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Company (2018-2023) ($ Millions)
Table 21. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Company (2018-2023)
Table 22. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sale Price by Company (2018-2023) & (US$/Unit)
Table 23. Key Manufacturers Glucagon-like peptide 1 (GLP-1)-based Therapies Producing Area Distribution and Sales Area
Table 24. Players Glucagon-like peptide 1 (GLP-1)-based Therapies Products Offered
Table 25. Glucagon-like peptide 1 (GLP-1)-based Therapies Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 26. New Products and Potential Entrants
Table 27. Mergers & Acquisitions, Expansion
Table 28. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Geographic Region (2018-2023) & (Units)
Table 29. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share Geographic Region (2018-2023)
Table 30. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Geographic Region (2018-2023) & ($ millions)
Table 31. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Geographic Region (2018-2023)
Table 32. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country/Region (2018-2023) & (Units)
Table 33. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country/Region (2018-2023)
Table 34. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country/Region (2018-2023) & ($ millions)
Table 35. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Country/Region (2018-2023)
Table 36. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2018-2023) & (Units)
Table 37. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country (2018-2023)
Table 38. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2018-2023) & ($ Millions)
Table 39. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Country (2018-2023)
Table 40. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type (2018-2023) & (Units)
Table 41. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2018-2023) & (Units)
Table 42. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region (2018-2023) & (Units)
Table 43. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Region (2018-2023)
Table 44. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Region (2018-2023) & ($ Millions)
Table 45. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Region (2018-2023)
Table 46. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type (2018-2023) & (Units)
Table 47. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2018-2023) & (Units)
Table 48. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2018-2023) & (Units)
Table 49. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country (2018-2023)
Table 50. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2018-2023) & ($ Millions)
Table 51. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Country (2018-2023)
Table 52. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type (2018-2023) & (Units)
Table 53. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2018-2023) & (Units)
Table 54. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2018-2023) & (Units)
Table 55. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country (2018-2023)
Table 56. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2018-2023) & ($ Millions)
Table 57. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Country (2018-2023)
Table 58. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type (2018-2023) & (Units)
Table 59. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2018-2023) & (Units)
Table 60. Key Market Drivers & Growth Opportunities of Glucagon-like peptide 1 (GLP-1)-based Therapies
Table 61. Key Market Challenges & Risks of Glucagon-like peptide 1 (GLP-1)-based Therapies
Table 62. Key Industry Trends of Glucagon-like peptide 1 (GLP-1)-based Therapies
Table 63. Glucagon-like peptide 1 (GLP-1)-based Therapies Raw Material
Table 64. Key Suppliers of Raw Materials
Table 65. Glucagon-like peptide 1 (GLP-1)-based Therapies Distributors List
Table 66. Glucagon-like peptide 1 (GLP-1)-based Therapies Customer List
Table 67. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Region (2024-2029) & (Units)
Table 68. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Forecast by Region (2024-2029) & ($ millions)
Table 69. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Country (2024-2029) & (Units)
Table 70. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Forecast by Country (2024-2029) & ($ millions)
Table 71. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Region (2024-2029) & (Units)
Table 72. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Forecast by Region (2024-2029) & ($ millions)
Table 73. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Country (2024-2029) & (Units)
Table 74. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Country (2024-2029) & (Units)
Table 76. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Forecast by Country (2024-2029) & ($ millions)
Table 77. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Type (2024-2029) & (Units)
Table 78. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 79. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Application (2024-2029) & (Units)
Table 80. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 81. Novo Nordisk Basic Information, Glucagon-like peptide 1 (GLP-1)-based Therapies Manufacturing Base, Sales Area and Its Competitors
Table 82. Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolios and Specifications
Table 83. Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 84. Novo Nordisk Main Business
Table 85. Novo Nordisk Latest Developments
Table 86. AstraZeneca Basic Information, Glucagon-like peptide 1 (GLP-1)-based Therapies Manufacturing Base, Sales Area and Its Competitors
Table 87. AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolios and Specifications
Table 88. AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 89. AstraZeneca Main Business
Table 90. AstraZeneca Latest Developments
Table 91. Eli Lily Basic Information, Glucagon-like peptide 1 (GLP-1)-based Therapies Manufacturing Base, Sales Area and Its Competitors
Table 92. Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolios and Specifications
Table 93. Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 94. Eli Lily Main Business
Table 95. Eli Lily Latest Developments
Table 96. GSK Basic Information, Glucagon-like peptide 1 (GLP-1)-based Therapies Manufacturing Base, Sales Area and Its Competitors
Table 97. GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolios and Specifications
Table 98. GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 99. GSK Main Business
Table 100. GSK Latest Developments
Table 101. Sanofi Basic Information, Glucagon-like peptide 1 (GLP-1)-based Therapies Manufacturing Base, Sales Area and Its Competitors
Table 102. Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolios and Specifications
Table 103. Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 104. Sanofi Main Business
Table 105. Sanofi Latest Developments
Table 106. Bristol-Myers Squibb Basic Information, Glucagon-like peptide 1 (GLP-1)-based Therapies Manufacturing Base, Sales Area and Its Competitors
Table 107. Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolios and Specifications
Table 108. Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 109. Bristol-Myers Squibb Main Business
Table 110. Bristol-Myers Squibb Latest Developments
Table 1. Glucagon-like peptide 1 (GLP-1)-based Therapies Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Glucagon-like peptide 1 (GLP-1)-based Therapies Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Exenatied
Table 4. Major Players of Liraglutide
Table 5. Major Players of Lixisenatide
Table 6. Major Players of Albiglutide
Table 7. Major Players of Dulaglutide
Table 8. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type (2018-2023) & (Units)
Table 9. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type (2018-2023)
Table 10. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Type (2018-2023) & ($ million)
Table 11. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Type (2018-2023)
Table 12. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sale Price by Type (2018-2023) & (US$/Unit)
Table 13. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2018-2023) & (Units)
Table 14. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application (2018-2023)
Table 15. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Application (2018-2023)
Table 16. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Application (2018-2023)
Table 17. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sale Price by Application (2018-2023) & (US$/Unit)
Table 18. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Company (2018-2023) & (Units)
Table 19. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Company (2018-2023)
Table 20. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Company (2018-2023) ($ Millions)
Table 21. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Company (2018-2023)
Table 22. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sale Price by Company (2018-2023) & (US$/Unit)
Table 23. Key Manufacturers Glucagon-like peptide 1 (GLP-1)-based Therapies Producing Area Distribution and Sales Area
Table 24. Players Glucagon-like peptide 1 (GLP-1)-based Therapies Products Offered
Table 25. Glucagon-like peptide 1 (GLP-1)-based Therapies Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 26. New Products and Potential Entrants
Table 27. Mergers & Acquisitions, Expansion
Table 28. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Geographic Region (2018-2023) & (Units)
Table 29. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share Geographic Region (2018-2023)
Table 30. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Geographic Region (2018-2023) & ($ millions)
Table 31. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Geographic Region (2018-2023)
Table 32. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country/Region (2018-2023) & (Units)
Table 33. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country/Region (2018-2023)
Table 34. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country/Region (2018-2023) & ($ millions)
Table 35. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Country/Region (2018-2023)
Table 36. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2018-2023) & (Units)
Table 37. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country (2018-2023)
Table 38. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2018-2023) & ($ Millions)
Table 39. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Country (2018-2023)
Table 40. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type (2018-2023) & (Units)
Table 41. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2018-2023) & (Units)
Table 42. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region (2018-2023) & (Units)
Table 43. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Region (2018-2023)
Table 44. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Region (2018-2023) & ($ Millions)
Table 45. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Region (2018-2023)
Table 46. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type (2018-2023) & (Units)
Table 47. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2018-2023) & (Units)
Table 48. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2018-2023) & (Units)
Table 49. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country (2018-2023)
Table 50. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2018-2023) & ($ Millions)
Table 51. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Country (2018-2023)
Table 52. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type (2018-2023) & (Units)
Table 53. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2018-2023) & (Units)
Table 54. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2018-2023) & (Units)
Table 55. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country (2018-2023)
Table 56. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2018-2023) & ($ Millions)
Table 57. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Country (2018-2023)
Table 58. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type (2018-2023) & (Units)
Table 59. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2018-2023) & (Units)
Table 60. Key Market Drivers & Growth Opportunities of Glucagon-like peptide 1 (GLP-1)-based Therapies
Table 61. Key Market Challenges & Risks of Glucagon-like peptide 1 (GLP-1)-based Therapies
Table 62. Key Industry Trends of Glucagon-like peptide 1 (GLP-1)-based Therapies
Table 63. Glucagon-like peptide 1 (GLP-1)-based Therapies Raw Material
Table 64. Key Suppliers of Raw Materials
Table 65. Glucagon-like peptide 1 (GLP-1)-based Therapies Distributors List
Table 66. Glucagon-like peptide 1 (GLP-1)-based Therapies Customer List
Table 67. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Region (2024-2029) & (Units)
Table 68. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Forecast by Region (2024-2029) & ($ millions)
Table 69. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Country (2024-2029) & (Units)
Table 70. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Forecast by Country (2024-2029) & ($ millions)
Table 71. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Region (2024-2029) & (Units)
Table 72. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Forecast by Region (2024-2029) & ($ millions)
Table 73. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Country (2024-2029) & (Units)
Table 74. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Country (2024-2029) & (Units)
Table 76. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Forecast by Country (2024-2029) & ($ millions)
Table 77. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Type (2024-2029) & (Units)
Table 78. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 79. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Application (2024-2029) & (Units)
Table 80. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 81. Novo Nordisk Basic Information, Glucagon-like peptide 1 (GLP-1)-based Therapies Manufacturing Base, Sales Area and Its Competitors
Table 82. Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolios and Specifications
Table 83. Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 84. Novo Nordisk Main Business
Table 85. Novo Nordisk Latest Developments
Table 86. AstraZeneca Basic Information, Glucagon-like peptide 1 (GLP-1)-based Therapies Manufacturing Base, Sales Area and Its Competitors
Table 87. AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolios and Specifications
Table 88. AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 89. AstraZeneca Main Business
Table 90. AstraZeneca Latest Developments
Table 91. Eli Lily Basic Information, Glucagon-like peptide 1 (GLP-1)-based Therapies Manufacturing Base, Sales Area and Its Competitors
Table 92. Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolios and Specifications
Table 93. Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 94. Eli Lily Main Business
Table 95. Eli Lily Latest Developments
Table 96. GSK Basic Information, Glucagon-like peptide 1 (GLP-1)-based Therapies Manufacturing Base, Sales Area and Its Competitors
Table 97. GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolios and Specifications
Table 98. GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 99. GSK Main Business
Table 100. GSK Latest Developments
Table 101. Sanofi Basic Information, Glucagon-like peptide 1 (GLP-1)-based Therapies Manufacturing Base, Sales Area and Its Competitors
Table 102. Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolios and Specifications
Table 103. Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 104. Sanofi Main Business
Table 105. Sanofi Latest Developments
Table 106. Bristol-Myers Squibb Basic Information, Glucagon-like peptide 1 (GLP-1)-based Therapies Manufacturing Base, Sales Area and Its Competitors
Table 107. Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Product Portfolios and Specifications
Table 108. Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 109. Bristol-Myers Squibb Main Business
Table 110. Bristol-Myers Squibb Latest Developments
LIST OF FIGURES
Figure 1. Picture of Glucagon-like peptide 1 (GLP-1)-based Therapies
Figure 2. Glucagon-like peptide 1 (GLP-1)-based Therapies Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Growth Rate 2018-2029 (Units)
Figure 7. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Exenatied
Figure 10. Product Picture of Liraglutide
Figure 11. Product Picture of Lixisenatide
Figure 12. Product Picture of Albiglutide
Figure 13. Product Picture of Dulaglutide
Figure 14. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type in 2022
Figure 15. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Type (2018-2023)
Figure 16. Glucagon-like peptide 1 (GLP-1)-based Therapies Consumed in Hospital
Figure 17. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market: Hospital (2018-2023) & (Units)
Figure 18. Glucagon-like peptide 1 (GLP-1)-based Therapies Consumed in Pharmacy
Figure 19. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market: Pharmacy (2018-2023) & (Units)
Figure 20. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application (2022)
Figure 21. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Application in 2022
Figure 22. Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market by Company in 2022 (Units)
Figure 23. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Company in 2022
Figure 24. Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market by Company in 2022 ($ Million)
Figure 25. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Company in 2022
Figure 26. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Geographic Region (2018-2023)
Figure 27. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Geographic Region in 2022
Figure 28. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales 2018-2023 (Units)
Figure 29. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue 2018-2023 ($ Millions)
Figure 30. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales 2018-2023 (Units)
Figure 31. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue 2018-2023 ($ Millions)
Figure 32. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales 2018-2023 (Units)
Figure 33. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue 2018-2023 ($ Millions)
Figure 34. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales 2018-2023 (Units)
Figure 35. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue 2018-2023 ($ Millions)
Figure 36. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country in 2022
Figure 37. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Country in 2022
Figure 38. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type (2018-2023)
Figure 39. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application (2018-2023)
Figure 40. United States Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 ($ Millions)
Figure 41. Canada Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 ($ Millions)
Figure 42. Mexico Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 ($ Millions)
Figure 43. Brazil Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 ($ Millions)
Figure 44. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Region in 2022
Figure 45. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Regions in 2022
Figure 46. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type (2018-2023)
Figure 47. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application (2018-2023)
Figure 48. China Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 ($ Millions)
Figure 49. Japan Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 ($ Millions)
Figure 50. South Korea Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 ($ Millions)
Figure 51. Southeast Asia Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 ($ Millions)
Figure 52. India Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 ($ Millions)
Figure 53. Australia Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 ($ Millions)
Figure 54. China Taiwan Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 ($ Millions)
Figure 55. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country in 2022
Figure 56. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Country in 2022
Figure 57. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type (2018-2023)
Figure 58. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application (2018-2023)
Figure 59. Germany Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 ($ Millions)
Figure 60. France Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 ($ Millions)
Figure 61. UK Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 ($ Millions)
Figure 62. Italy Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 ($ Millions)
Figure 63. Russia Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 ($ Millions)
Figure 64. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country in 2022
Figure 65. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Country in 2022
Figure 66. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type (2018-2023)
Figure 67. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application (2018-2023)
Figure 68. Egypt Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 ($ Millions)
Figure 69. South Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 ($ Millions)
Figure 70. Israel Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 ($ Millions)
Figure 71. Turkey Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 ($ Millions)
Figure 72. GCC Country Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 ($ Millions)
Figure 73. Manufacturing Cost Structure Analysis of Glucagon-like peptide 1 (GLP-1)-based Therapies in 2022
Figure 74. Manufacturing Process Analysis of Glucagon-like peptide 1 (GLP-1)-based Therapies
Figure 75. Industry Chain Structure of Glucagon-like peptide 1 (GLP-1)-based Therapies
Figure 76. Channels of Distribution
Figure 77. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Forecast by Region (2024-2029)
Figure 78. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share Forecast by Region (2024-2029)
Figure 79. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share Forecast by Type (2024-2029)
Figure 80. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share Forecast by Type (2024-2029)
Figure 81. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share Forecast by Application (2024-2029)
Figure 82. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share Forecast by Application (2024-2029)
Figure 1. Picture of Glucagon-like peptide 1 (GLP-1)-based Therapies
Figure 2. Glucagon-like peptide 1 (GLP-1)-based Therapies Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Growth Rate 2018-2029 (Units)
Figure 7. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Exenatied
Figure 10. Product Picture of Liraglutide
Figure 11. Product Picture of Lixisenatide
Figure 12. Product Picture of Albiglutide
Figure 13. Product Picture of Dulaglutide
Figure 14. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type in 2022
Figure 15. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Type (2018-2023)
Figure 16. Glucagon-like peptide 1 (GLP-1)-based Therapies Consumed in Hospital
Figure 17. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market: Hospital (2018-2023) & (Units)
Figure 18. Glucagon-like peptide 1 (GLP-1)-based Therapies Consumed in Pharmacy
Figure 19. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market: Pharmacy (2018-2023) & (Units)
Figure 20. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application (2022)
Figure 21. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Application in 2022
Figure 22. Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market by Company in 2022 (Units)
Figure 23. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Company in 2022
Figure 24. Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market by Company in 2022 ($ Million)
Figure 25. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Company in 2022
Figure 26. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Geographic Region (2018-2023)
Figure 27. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Geographic Region in 2022
Figure 28. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales 2018-2023 (Units)
Figure 29. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue 2018-2023 ($ Millions)
Figure 30. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales 2018-2023 (Units)
Figure 31. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue 2018-2023 ($ Millions)
Figure 32. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales 2018-2023 (Units)
Figure 33. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue 2018-2023 ($ Millions)
Figure 34. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales 2018-2023 (Units)
Figure 35. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue 2018-2023 ($ Millions)
Figure 36. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country in 2022
Figure 37. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Country in 2022
Figure 38. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type (2018-2023)
Figure 39. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application (2018-2023)
Figure 40. United States Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 ($ Millions)
Figure 41. Canada Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 ($ Millions)
Figure 42. Mexico Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 ($ Millions)
Figure 43. Brazil Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 ($ Millions)
Figure 44. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Region in 2022
Figure 45. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Regions in 2022
Figure 46. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type (2018-2023)
Figure 47. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application (2018-2023)
Figure 48. China Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 ($ Millions)
Figure 49. Japan Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 ($ Millions)
Figure 50. South Korea Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 ($ Millions)
Figure 51. Southeast Asia Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 ($ Millions)
Figure 52. India Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 ($ Millions)
Figure 53. Australia Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 ($ Millions)
Figure 54. China Taiwan Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 ($ Millions)
Figure 55. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country in 2022
Figure 56. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Country in 2022
Figure 57. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type (2018-2023)
Figure 58. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application (2018-2023)
Figure 59. Germany Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 ($ Millions)
Figure 60. France Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 ($ Millions)
Figure 61. UK Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 ($ Millions)
Figure 62. Italy Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 ($ Millions)
Figure 63. Russia Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 ($ Millions)
Figure 64. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country in 2022
Figure 65. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Country in 2022
Figure 66. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type (2018-2023)
Figure 67. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application (2018-2023)
Figure 68. Egypt Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 ($ Millions)
Figure 69. South Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 ($ Millions)
Figure 70. Israel Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 ($ Millions)
Figure 71. Turkey Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 ($ Millions)
Figure 72. GCC Country Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2018-2023 ($ Millions)
Figure 73. Manufacturing Cost Structure Analysis of Glucagon-like peptide 1 (GLP-1)-based Therapies in 2022
Figure 74. Manufacturing Process Analysis of Glucagon-like peptide 1 (GLP-1)-based Therapies
Figure 75. Industry Chain Structure of Glucagon-like peptide 1 (GLP-1)-based Therapies
Figure 76. Channels of Distribution
Figure 77. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Forecast by Region (2024-2029)
Figure 78. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share Forecast by Region (2024-2029)
Figure 79. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share Forecast by Type (2024-2029)
Figure 80. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share Forecast by Type (2024-2029)
Figure 81. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share Forecast by Application (2024-2029)
Figure 82. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share Forecast by Application (2024-2029)
